The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study

Table 1

Baseline characteristics of the patients.

Characteristic	Classification	Number of patients (%); 𝑁=114
	No	23 (20.2)
Pretreatment drug	Yes	91 (79.8)
	𝛼1-blocker	91 (79.8)
	Anticholinergic agent	9 (7.9)
	50 to 65	14 (12.3)
	65 to 70	14 (12.3)
	70 to 75	39 (34.2)
Age (yrs)	75 to 80	27 (23.7)
	≥80	20 (17.5)
	Mean ± SD	73.0 ± 6.8
	Median	73.0
	Range (Min–Max)	57.0–89.0
	≤1.0	7 (6.5)
	>1.0 and ≤2.0	12 (11.2)
PSA at Week 0^† (ng/mL)	>2.0 and ≤4.0	31 (29.0)
	>4.0 and ≤6.0	22 (20.6)
	>6.0 and ≤10.0	31 (29.0)
	>10.0	4 (3.7)
	Mean	3.66
	20 to 30	22 (20.2)
	30 to 40	18 (16.5)
Prostate volume (mL)	40 to 55	31 (28.4)
	55 to 80	29 (26.6)
	≥80	9 (8.3)
	Mean	46.15

PSA: prostate-specific antigen; †The day of the first dose.